The Derm/Rheum Clinic: Treatment Strategies for Patients with Cutaneous Autoimmune Disease
Effective treatment strategies are available for cutaneous autoimmune disease, according to Dr. Anthony Fernandez, director of medical and inpatient dermatology at the Cleveland Clinic. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Fernandez, who explains how the severity of the disease impacts the most appropriate treatment option. …
Effective treatment strategies are available for cutaneous autoimmune disease, according to Dr. Anthony Fernandez, director of medical and inpatient dermatology at the Cleveland Clinic. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Fernandez, who explains how the severity of the disease impacts the most appropriate treatment option. … 
Histopathology can be rendered useless without good clinical information, according to Dr. Olayemi Sokumbi, a dermatologist and dermatopathologist with Mayo Clinic. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Sokumbi about traps to avoid in challenging clinicopathologic scenarios. Learn how not to miss a diagnosis of dermatomyosit … 
Collagen vascular diseases encompass a group of autoimmune disorders that can have a profound impact on an individual's health and quality of life. At the 2023 Skin of Color Update, Dr. Ted Rosen, Professor and Vice-Chair of Dermatology at Baylor College of Medicine, explained how these conditions uniquely impact individuals with skin of color.
Missed the lecture?? Explore key insights and pear … 
Intravenous immune globulin (IVIG) is a concentrate of pooled immunoglobulins derived from plasma donors. Its unique mechanism of action expands the utility of the medication to a variety of conditions. We continue our series, Therapeutic Cheat Sheet, with a closer look at IVIG, which is FDA-approved for the treatment of dermatologic conditions including dermatomyositis, Kawasaki disease, ITP, and … 
Rituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other … 